CELZ Stock Analysis: Buy, Sell, or Hold?
CELZ - Creative Medical Technology Holdings, Inc. Common Stock
$1.21
-0.10 (-7.63%)
▼
5d:
+10.0%
30d:
+49.35%
90d:
-49.37%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When CELZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CELZ shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CELZ shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CELZ is currently trading at $1.21, which is considered extended relative to its 30-day fair value range of $0.73 to $1.18.
Technical Outlook: Technically, CELZ is in a strong downtrend. Immediate support is located at $1.06, while resistance sits at $1.46. Short-term momentum is weak, with the stock down 7.6% recently.
Market Sentiment: CELZ scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+1552.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CELZ is in a strong downtrend. Immediate support is located at $1.06, while resistance sits at $1.46. Short-term momentum is weak, with the stock down 7.6% recently.
Market Sentiment: CELZ scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+1552.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.73 -
$1.18
Company Quality Score
31/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
15.8%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (21/100)
- BEARISH: Downward momentum (-7.6%)
- BULLISH: Trading 1552.9% below Wall St target ($20.00)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.73 -
$1.18
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$1.46
Current Trend
Strong Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.38
Wall Street Target
$20.00
(+1552.9%)
Earnings Growth (YoY)
358.9%
Share & Embed Analysis
Last updated: August 24, 2026 9:46 PM ET
Data refreshes hourly during market hours. Next update: 10:46 PM
Data refreshes hourly during market hours. Next update: 10:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CELZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 46 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 45 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 68 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 51 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 39 SELL |
